神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Neuropeptide Y (NPY) ,etc. by FLIA (Flow Luminescence Immunoassay)
NP-Y; PYY4; CPON; Pro-neuropeptide Y; Neuropeptide tyrosine; C-flanking peptide of NPY
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)ULMA879Bo
- 物種Bos taurus; Bovine (Cattle，牛) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)1.5h
- 檢測(cè)范圍1.95-2000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.65 pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 1415 ¥ 1469 ¥ 1551 ¥ 1660 ¥ 1769 ¥ 1932 ¥ 2177 ¥ 2721 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 88-96 | 92 |
| EDTA plasma(n=5) | 78-93 | 82 |
| heparin plasma(n=5) | 98-105 | 101 |
| sodium citrate plasma(n=5) | 87-96 | 92 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-101% | 93-105% | 89-96% | 83-95% |
| EDTA plasma(n=5) | 78-91% | 93-104% | 81-105% | 86-98% |
| heparin plasma(n=5) | 96-104% | 81-96% | 82-94% | 78-95% |
| sodium citrate plasma(n=5) | 87-94% | 81-97% | 90-104% | 98-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠、檢測(cè)溶液A）標(biāo)準(zhǔn)品或樣本50μL及磁珠10μL，加檢測(cè)溶液A50μL，
37°C酶標(biāo)板振蕩器孵育60分鐘；
3. 磁吸洗板3次；
4. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
5. 磁吸洗板3次；
6. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠、標(biāo)記VEGFA，標(biāo)記的神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)和未標(biāo)記的神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競(jìng)爭(zhēng)結(jié)合，然后將未結(jié)合物洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈負(fù)相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA879Bo01 | 神經(jīng)肽Y(NPY)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA879Bo01 | 神經(jīng)肽Y(NPY)多克隆抗體 | WB; IHC; ICC; IP. |
| UMAA879Bo21 | 神經(jīng)肽Y(NPY)單克隆抗體 | WB; IHC; ICC; IP. |
| UCEA879Bo | 神經(jīng)肽Y(NPY)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA879Bo | 神經(jīng)肽Y(NPY)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Hemodialysis International | Is there any interaction of resistin and adiponectin levels with protein‐energy wasting among patients with chronic kidney disease [Onlinelibrary: hdi.12072] |
| Journal of Pediatric Endocrinology and Metabolism | Changes in growth pattern, leptin ghrelin and neuropeptide Y levels after adenotonsillectomy in prepubertal children [Degruyter: Source] |
| Ren Fail. | The role of adipocytokines on depressive symptoms of patients with chronic kidney disease [Pubmed: 23879728] |
| Coronary Artery Disease | The relationship of plasma neuropeptide Y levels with coronary collateral development. [Pubmed: 24077326] |
| Coronary Artery Disease | The relationship of plasma neuropeptide Y levels with coronary collateral development [Lww:Source] |
| Toxicology Letters | Possible role of serotonin and neuropeptide Y on the disruption of the reproductive axis activity by perfluorooctane sulfonate [Pubmed:25623392] |
| J Neurosurg Anesthesiol | High Plasma Levels of Neuropeptide Y Correlate With Good Clinical Outcome But are not Correlated to Cerebral Blood Flow or Vasospasm After Subarachnoid Hemorrhage [PubMed: 25955865] |
| Journal of Diabetes Research | High Intensity Aerobic Exercise Training Improves Deficits of Cardiovascular Autonomic Function in a Rat Model of Type 1 Diabetes Mellitus with Moderate … [Pubmed:26885531] |
| Archives of Gynecology and Obstetrics | Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate [pubmed:27604241] |
| basic & clinical pharmacology & toxicology | Effects of Di-isononyl Phthalate on Neuropeptide Y Expression in Differentiating Human Neuronal Cells. [pubmed:27625336] |
| Acta?Neurobiologiae Experimentalis | Aberrant changes of somatostatin and neuropeptide Y in brain of a genetic rat model for epilepsy: tremor rat [pubmed:27685769] |
| Cardiovascular?research | Nur77 protects against adverse cardiac remodelling by limiting Neuropeptide Y signalling in the sympathoadrenal-cardiac axis [Pubmed:29850786] |
| Journal of Periodontology | Salivary neuropeptides, stress, and periodontitis [Pubmed:28914594] |
| Neuropeptides | Mechanisms of sustained long-term weight loss after RYGB: α-MSH is a key factor [Pubmed:29685637] |
| Pharmacology | Melatonin Induces Osteoblastic Differentiation of Mesenchymal Stem Cells and Promotes Fracture Healing in a Rat Model of Femoral Fracture via Neuropeptide Y?… [Pubmed: 30227410] |
| Marmara Medical Journal | Investigation of the relationship between insulin resistance and neuropeptide Y levels in polycystic ovary syndrome [] |
| Marmara Medical Journal | Investigation of the relationship between insulin resistance and neuropeptide Y levels in polycystic ovary syndrome. [] |
| neurochemical research | Sevoflurane Induces Hippocampal Neuronal Apoptosis by Altering the Level of Neuropeptide Y in Neonatal Rats. [Pubmed: 32378074] |
| Hum Psychopharmacol | Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double?\blind randomized??- [33245168] |
| Arch Toxicol | Serotonin involvement in okadaic acid-induced diarrhoea in vivo [34148100] |
